来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

休市中 05-02 16:08:25

14.720

+0.600

+4.25%

最高15.100	最低13.800	成交量130.30万
今开14.200	昨收14.120	日振幅9.21%
总市值60.06亿	流通市值60.06亿	总股本4.08亿
成交额1,917万	换手率0.32%	流通股本4.08亿
市净率6.96	ROE-31.61%	每股收益-0.76
52周最高17.780	52周最低3.900	市盈率-19.31
股息0.00	股息收益率0.00	ROA-19.07%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":14.72,"timestamp":1746173305031,"preClose":14.12,"halted":0,"volume":1303000,"delay":0,"floatShares":408000000,"shares":408000000,"eps":-0.7622307877853128,"marketStatus":"休市中","change":0.6,"latestTime":"05-02 16:08:25","open":14.2,"high":15.1,"low":13.8,"amount":19167835,"amplitude":0.092068,"askPrice":14.72,"askSize":11000,"bidPrice":14.52,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-0.7622307877853128,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":14.12,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.5754537825853144,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"2532857014","title":"晶泰控股盘中异动 早盘快速跳水5.04%报4.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532857014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532857014?lang=zh_cn&edition=full","pubTime":"2025-05-02 10:00","pubTimestamp":1746151232,"startTime":"0","endTime":"0","summary":"2025年05月02日早盘10时00分，晶泰控股股票出现异动，股价急速下跌5.04%。截至发稿，该股报4.900港元/股，成交量479.125万股，换手率0.12%，振幅6.20%。资金方面，该股资金流入495.568万港元，流出1687.67万港元。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。晶泰控股股票所在的生物技术行业中，整体跌幅为1.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050210003294ea5a76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050210003294ea5a76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02228","02105","BK1161","BK1617","09966","BK1574","BK1583","06998","BK1141"],"gpt_icon":0},{"id":"2532463852","title":"来凯医药-B盘中异动 股价大涨5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532463852","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532463852?lang=zh_cn&edition=full","pubTime":"2025-05-02 09:49","pubTimestamp":1746150582,"startTime":"0","endTime":"0","summary":"2025年05月02日早盘09时49分，来凯医药-B股票出现波动，股价大幅拉升5.52%。截至发稿，该股报14.900港元/股，成交量31.75万股，换手率0.08%，振幅8.36%。来凯医药-B股票所在的生物技术行业中，整体跌幅为1.49%。其相关个股中，康宁杰瑞制药-B、创胜集团-B、来凯医药-B涨幅较大，振幅较大的相关个股有康宁杰瑞制药-B、嘉和生物-B、北海康成-B，振幅分别为9.91%、6.91%、6.71%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050209494294ea588f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050209494294ea588f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2531083315","title":"来凯医药-B04月30日主力净流出141.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2531083315","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531083315?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000941,"startTime":"0","endTime":"0","summary":"04月30日, 来凯医药-B股价跌3.42%，报收14.12元，成交金额2225.3万元，换手率0.39%，振幅4.10%，量比0.65。来凯医药-B今日主力资金净流出141.8万元，上一交易日主力净流入223.7万元。该股近5个交易日下跌1.12%，主力资金累计净流出180.9万元；近20日主力资金累计净流入569.0万元，其中净流入天数为10日。该股主力净额占比0.02%，港股市场排名2526/2646。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171041a46d7567&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171041a46d7567&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2530127418","title":"港股异动 | 来凯医药-B(02105)现涨近6% 自主研发的新一代PI3Kα抑制剂及WRN抑制剂入选AACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530127418","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530127418?lang=zh_cn&edition=full","pubTime":"2025-04-28 11:21","pubTimestamp":1745810514,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B现涨近6%，截至发稿，涨5.86%，报14.46港元，成交额1712.35万港元。消息面上，2025年度美国癌症研究协会年会召开在即，来凯医药有两项临床前自主研发的癌症新药成果入选——全突变选择性PI3Kα抑制剂LAE118，及新型强效选择性WRN抑制剂LAE122。同时，来自ClinicalTrials网站的信息也显示，该研究计划于2025年4月底启动临床入组，预计在2025年8月结束。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161","WRN","BK4168"],"gpt_icon":0},{"id":"2530971664","title":"来凯医药-B盘中异动 早盘股价大涨5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530971664","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530971664?lang=zh_cn&edition=full","pubTime":"2025-04-28 10:32","pubTimestamp":1745807531,"startTime":"0","endTime":"0","summary":"2025年04月28日早盘10时32分，来凯医药-B股票出现异动，股价大幅上涨5.42%。截至发稿，该股报14.400港元/股，成交量72.3万股，换手率0.18%，振幅9.37%。资金方面，该股资金流入554.483万港元，流出364.8万港元。来凯医药-B股票所在的生物技术行业中，整体跌幅为1.05%。其相关个股中，荣昌生物、和铂医药-B、来凯医药-B涨幅较大，振幅较大的相关个股有中国抗体-B、荣昌生物、云康集团，振幅分别为13.74%、12.77%、12.71%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042810321194e5445c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042810321194e5445c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2530903642","title":"来凯医药-B04月25日主力净流出564万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2530903642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530903642?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:16","pubTimestamp":1745569014,"startTime":"0","endTime":"0","summary":"04月25日, 来凯医药-B股价跌6.18%，报收13.66元，成交金额3784万元，换手率0.67%，振幅11.68%，量比0.90。来凯医药-B今日主力资金净流出564万元，上一交易日主力净流入227万元。该股近5个交易日上涨21.06%，主力资金累计净流入1048万元；近20日主力资金累计净流入888万元，其中净流入天数为10日。该股主力净额占比0.10%，港股市场排名2611/2647。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170833a46693c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170833a46693c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2530945305","title":"来凯医药-B盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530945305","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530945305?lang=zh_cn&edition=full","pubTime":"2025-04-25 10:00","pubTimestamp":1745546453,"startTime":"0","endTime":"0","summary":"2025年04月25日早盘10时00分，来凯医药-B股票出现异动，股价大幅下挫5.08%。截至发稿，该股报13.820港元/股，成交量67.05万股，换手率0.16%，振幅8.79%。资金方面，该股资金流入296.591万港元，流出556.382万港元。来凯医药-B股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，晶泰控股、维升药业-B、云顶新耀-B涨幅较大，振幅较大的相关个股有创胜集团-B、来凯医药-B、科伦博泰生物-B，振幅分别为10.94%、8.79%、7.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425100053a466265e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425100053a466265e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2529609656","title":"来凯医药-B04月24日主力净流入227万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529609656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529609656?lang=zh_cn&edition=full","pubTime":"2025-04-24 16:16","pubTimestamp":1745482560,"startTime":"0","endTime":"0","summary":"04月24日, 来凯医药-B股价涨1.96%，报收14.56元，成交金额3138万元，换手率0.53%，振幅8.96%，量比0.73。来凯医药-B今日主力资金净流入227万元，上一交易日主力净流出53万元。该股近5个交易日上涨16.10%，主力资金累计净流入1451万元；近20日主力资金累计净流入1481万元，其中净流入天数为11日。该股主力净额占比0.04%，港股市场排名113/2646。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165931a6c655df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165931a6c655df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2529917618","title":"来凯医药-B盘中异动 大幅上涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529917618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529917618?lang=zh_cn&edition=full","pubTime":"2025-04-24 09:39","pubTimestamp":1745458761,"startTime":"0","endTime":"0","summary":"2025年04月24日早盘09时39分，来凯医药-B股票出现波动，股价快速拉升5.18%。截至发稿，该股报15.020港元/股，成交量27.35万股，换手率0.07%，振幅5.60%。资金方面，该股资金流入263.886万港元，流出106.833万港元。来凯医药-B股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，荣昌生物、宜明昂科-B、亚盛医药-B涨幅较大，振幅较大的相关个股有乐普生物-B、诺诚健华、亚盛医药-B，振幅分别为6.44%、6.18%、5.60%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042409392194e047c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042409392194e047c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2529694833","title":"来凯医药(2105.HK)自主研发的新一代PI3Kα抑制剂及WRN抑制剂入选2025美国癌症研究协会年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2529694833","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529694833?lang=zh_cn&edition=full","pubTime":"2025-04-24 08:38","pubTimestamp":1745455106,"startTime":"0","endTime":"0","summary":"2025年4月24日——全球最权威的学术会议之一——2025年度美国癌症研究协会年会召开在即，来凯医药有两项临床前自主研发的癌症新药成果入选——全突变选择性PI3Kα抑制剂LAE118，及新型强效选择性WRN抑制剂LAE122。因此，开发一种能够更有效抑制螺旋结构域突变的新一代PI3Kα抑制剂具有重要的临床意义。目前全突变选择性PI3Kα抑制剂还未有新药成功上市，LAE118以潜在最佳的疗效成为新一代PI3Kα抑制剂的有力竞争者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/24083849813069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4168","WRN","02105","BK1161"],"gpt_icon":0},{"id":"2529257891","title":"来凯医药-B04月23日主力净流出53万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2529257891","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529257891?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:16","pubTimestamp":1745396178,"startTime":"0","endTime":"0","summary":"04月23日, 来凯医药-B股价跌1.52%，报收14.28元，成交金额3314万元，换手率0.56%，振幅7.17%，量比0.76。来凯医药-B今日主力资金净流出53万元，上一交易日主力净流入1410万元。该股近5个交易日上涨19.00%，主力资金累计净流入1412万元；近20日主力资金累计净流入1244万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423170952a463acbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423170952a463acbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2529337219","title":"港股恒指涨0.78% 科指涨0.24% 医药股集体大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2529337219","media":"青岛财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529337219?lang=zh_cn&edition=full","pubTime":"2025-04-22 18:58","pubTimestamp":1745319483,"startTime":"0","endTime":"0","summary":"4月22日，港股三大指数午后回暖转涨，截至收盘，恒生指数涨0.78%，报21562.32点，恒生科技指数涨0.24%，国企指数涨0.68%。黄金股午后有所回落，赤峰黄金涨超8%。多家港股创新药企近期发布财报，成绩亮眼，还有部分港股上市药企在研产品取得阶段性突破。中泰国际指出，关税对港股医药行业龙头企业影响有限。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422190230974088b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422190230974088b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","SGXZ81163826.USD","BK0037","600988","02105","BK0056","159938","BK0242","SGXZ49509284.SGD","BK0132","BK0127"],"gpt_icon":0},{"id":"2529328913","title":"港股收盘(04.22) | 恒指收涨0.78% 医药、黄金股表现强势 小米集团-W(01810)收涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529328913","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529328913?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:43","pubTimestamp":1745311432,"startTime":"0","endTime":"0","summary":"截止收盘，恒生指数涨0.78%或167.18点，报21562.32点，全日成交额2513.82亿港元；恒生国企指数涨0.68%，报7950.79点；恒生科技指数涨0.24%，报4899.21点。蓝筹股表现小米集团-W表现亮眼。截至收盘，涨5.84%，报44.4港元，成交额122.9亿港元，贡献恒指71.47点。截至收盘，赤峰黄金涨8.59%，报32.25港元；山东黄金涨7.31%，报25.7港元；招金矿业涨5.71%，报20港元；紫金矿业涨4.65%，报18.02港元。截至收盘，涨11.7%，报21港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348827113.USD","BK1618","BK1502","00551","LU0572944931.SGD","HSTECH","LU1719994722.HKD","LU0359202008.SGD","09923","BK1253","BK1198","LU0456827905.SGD","LU2097828714.EUR","02833","LU0823397285.USD","LU1868838027.USD","LU1981816686.USD","81810","LU0348816934.USD","LU1956131251.USD","HHImain","LU0611395673.USD","LU2097828474.EUR","LU2097828805.USD","09939","02105","159562","513600","BK1544","LU1251922891.USD","LU0348814723.USD","LU0327786744.USD","MCHmain","LU0871576103.HKD","LU0700851271.USD","09863","HXXD.SI","LU0149721374.USD","HSI","LU0359201612.USD","YANG","LU0164880469.USD","XIACY","LU0320764599.SGD","BK1521","159938","01810"],"gpt_icon":1},{"id":"2529732141","title":"来凯医药-B04月22日获主力加仓1410万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529732141","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529732141?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:15","pubTimestamp":1745309758,"startTime":"0","endTime":"0","summary":"04月22日, 来凯医药-B股价涨26.53%，报收14.50元，成交金额9141万元，换手率1.61%，振幅27.40%，量比2.97。来凯医药-B今日主力资金净流入1410万元，上一交易日主力净流入26万元。该股近5个交易日上涨35.90%，主力资金累计净流入1607万元；近20日主力资金累计净流入1244万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170938a6c38b0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170938a6c38b0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2529639339","title":"来凯医药-B涨幅持续扩大逾21% 礼来持续加码ActRII靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=2529639339","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529639339?lang=zh_cn&edition=full","pubTime":"2025-04-22 10:28","pubTimestamp":1745288880,"startTime":"0","endTime":"0","summary":"　　来凯医药-B早盘涨幅持续扩大，股价上涨21.29%，现报13.90港元，成交额2226.77万港元。　　2025年4月，一则来自全球临床试验注册平台ClinicalTrials网站的信息显示，来凯医药更新了其自研管线LAE102针对肥胖症在美国的一项I期临床试验的相关信息。一个引人注意的变化是：修订后的临床方案，出现了合作伙伴礼来的名字。同时，来自ClinicalTrials网站的信息也显示，该研究计划于2025年4月底启动临床入组，预计在2025年8月结束。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-22/doc-inetyyff5634636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1061106388.HKD","BK4581","IE00BK4W5L77.USD","LU2361044949.HKD","LU0471298777.SGD","LU2750360641.GBP","LU0823416689.USD","BK4534","IE00BFTCPJ56.SGD","LU0097036916.USD","IE0004445239.USD","LU1623119135.USD","LU1804176565.USD","LU1814569148.SGD","LU1868836591.USD","LU1917777945.USD","LU2237443549.SGD","LU0882574139.USD","LU0203202063.USD","LU1720051108.HKD","SG9999017495.SGD","LU0122379950.USD","LU0689472784.USD","LU1551013342.USD","LU2361044865.SGD","LU0354030511.USD","LU1868836914.USD","IE00BJJMRZ35.SGD","LU0882574055.USD","SG9999014898.SGD","LU2491050154.USD","IE00B2B36J28.USD","LU1280957306.USD","LU2211815571.USD","LU1868837136.USD","LU2237443622.USD","LU2106854487.HKD","LU2237443465.HKD","LU1988902786.USD","LU0943347566.SGD","SGXZ31699556.SGD","LU1035775433.USD","LU2023250504.SGD","LU2063271972.USD","LU2471134879.HKD","LU2471134952.CNY","IE00B4R5TH58.HKD","02105","LU2552382058.USD"],"gpt_icon":0},{"id":"2529360047","title":"港股异动 | 来凯医药-B(02105)现涨超15% 礼来持续加码ActRII靶点 LAE102美国1期启动在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2529360047","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529360047?lang=zh_cn&edition=full","pubTime":"2025-04-22 10:09","pubTimestamp":1745287788,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B现涨超15%，截至发稿，涨13.09%，报12.96港元，成交额1277.08万港元。消息面上，2025年4月，一则来自全球临床试验注册平台ClinicalTrials网站的信息显示，来凯医药更新了其自研管线LAE102针对肥胖症在美国的一项I期临床试验的相关信息。同时，来自ClinicalTrials网站的信息也显示，该研究计划于2025年4月底启动临床入组，预计在2025年8月结束。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1291159041.SGD","LU1551013342.USD","LU0456855351.SGD","SG9999015952.SGD","LU0114720955.EUR","LU0106261372.USD","LU1868836591.USD","LU0289739699.SGD","LU2361044865.SGD","LU0385154629.USD","LU1267930730.SGD","BK4588","02105","LU2265009873.SGD","SGXZ31699556.SGD","LU0466842654.USD","LU0820561818.USD","LU1093756168.USD","LU1988902786.USD","LU2237443382.USD","LU2471134523.USD","LU1868836757.USD","LU0417517546.SGD","LU0354030511.USD","LU2361044949.HKD","LU2471134796.USD","LU2552382058.USD","LU0708995401.HKD","LU2063271972.USD","IE00B1BXHZ80.USD","LU1804176565.USD","LU0122379950.USD","IE0009355771.USD","LU0203202063.USD","LU0006306889.USD","LU1232071149.USD","LU1548497426.USD","LU1868837300.USD","LU1720051108.HKD","LU1057294990.SGD","LU2023250504.SGD","LU2750360997.AUD","SGXZ51526630.SGD","BK4534","LU1868837136.USD","SG9999017495.SGD","LU1069344957.HKD","LU2750360641.GBP","SG9999018857.SGD"],"gpt_icon":1},{"id":"2529367183","title":"【港股医药股走强 歌礼制药涨近18%】截至发稿，歌礼制药-B(01672.HK)涨17.81%、荣昌生物(09995.HK)涨10.06%、映恩生物-B(09606.HK)涨9%、来凯生物-B(02105.HK)涨8.25%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529367183","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529367183?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:55","pubTimestamp":1745286903,"startTime":"0","endTime":"0","summary":"截至发稿，歌礼制药-B(01672.HK)涨17.81%、荣昌生物(09995.HK)涨10.06%、映恩生物-B(09606.HK)涨9%、来凯生物-B(02105.HK)涨8.25%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22095549737746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688331","LU2148510915.USD","09995","LU1064130708.USD","BK1574","LU1969619763.USD","LU1064131003.USD","01672","LU2328871848.SGD","BK1583","BK1161","BK1191","02105","01477","BK1515","159718","BK0239"],"gpt_icon":0},{"id":"2529366425","title":"增肌减脂新一代靶点：礼来携手来凯医药-B(02105)，美国I期临床启动在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2529366425","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529366425?lang=zh_cn&edition=full","pubTime":"2025-04-22 08:56","pubTimestamp":1745283360,"startTime":"0","endTime":"0","summary":"2025年4月，一则来自全球临床试验注册平台ClinicalTrials网站的信息显示，港股上市的Biotech公司来凯医药更新了其自研管线LAE102针对肥胖症在美国的一项I期临床试验的相关信息。此前，礼来已经完成了一项约500人规模的Bimagrumab与司美格鲁肽联用的临床试验。截至目前，礼来尚未公布Bimagrumab与司美格鲁肽联用的具体临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2361044865.SGD","LU0079474960.USD","LU2211815571.USD","LU1989771016.USD","LU0471298694.HKD","LU2264538146.SGD","IE0009355771.USD","LU0203202063.USD","LU2471134952.CNY","SG9999001176.SGD","LU2471134523.USD","LU1988902786.USD","SG9999014880.SGD","LU0466842654.USD","LU1814569148.SGD","IE00B1BXHZ80.USD","LU2265009873.SGD","LU2063271972.USD","02105","SG9999015945.SGD","LU0354030511.USD","SG9999001176.USD","LU2491049909.HKD","LU1291159041.SGD","LU0943347566.SGD","BK4533","LU0109391861.USD","LU0882574139.USD","LU0203201768.USD","SG9999015952.SGD","SGXZ31699556.SGD","LU0689472784.USD","LU0385154629.USD","LU1917777945.USD","LU0122379950.USD","LU1804176565.USD","LU0114720955.EUR","IE00B2B36J28.USD","LU0820561909.HKD","BK4534","SG9999014898.SGD","LU0256863902.USD","LU2552382058.USD","LU1868836757.USD","SG9999018857.SGD","LLY","LU0097036916.USD","LU2106854487.HKD","LU2324357040.USD","LU0820561818.USD"],"gpt_icon":1},{"id":"2528373796","title":"来凯医药-B04月17日主力净流入26万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2528373796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528373796?lang=zh_cn&edition=full","pubTime":"2025-04-17 16:15","pubTimestamp":1744877716,"startTime":"0","endTime":"0","summary":"04月17日, 来凯医药-B股价涨1.42%，报收11.46元，成交金额1443万元，换手率0.31%，振幅6.55%，量比0.50。来凯医药-B今日主力资金净流入26万元，上一交易日主力净流出161万元。该股近5个交易日上涨22.75%，主力资金累计净流入292万元；近20日主力资金累计净流出216万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417165932a6bdb3b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417165932a6bdb3b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2528782169","title":"来凯医药-B盘中异动 股价大涨5.49%报11.920港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528782169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528782169?lang=zh_cn&edition=full","pubTime":"2025-04-17 09:36","pubTimestamp":1744853785,"startTime":"0","endTime":"0","summary":"2025年04月17日早盘09时36分，来凯医药-B股票出现异动，股价快速上涨5.49%。截至发稿，该股报11.920港元/股，成交量7.05万股，换手率0.02%，振幅3.72%。资金方面，该股资金流入20.457万港元，流出40.465万港元。来凯医药-B股票所在的生物技术行业中，整体跌幅为0.95%。其相关个股中，来凯医药-B、云康集团、映恩生物-B涨幅较大，振幅较大的相关个股有映恩生物-B、康诺亚-B、巨子生物，振幅分别为7.05%、6.36%、5.02%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041709362594d815f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041709362594d815f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.0776},{"period":"1month","weight":0.0455},{"period":"3month","weight":0.5914},{"period":"6month","weight":0.6123},{"period":"1year","weight":1.3072},{"period":"ytd","weight":0.571}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":-0.0301},{"period":"3month","weight":0.1127},{"period":"6month","weight":0.0974},{"period":"1year","weight":0.236},{"period":"ytd","weight":0.1219}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}